Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Luyan Pharma Co., Ltd. is a Chinese pharmaceutical company specializing in the research, development, and manufacturing of a diverse range of medical products, including traditional Chinese medicine and chemical drugs. The company operates primarily in China but is expanding its footprint in international markets, leveraging its extensive distribution network and strong R&D capabilities to differentiate itself in a competitive landscape.
Luyan Pharma generates revenue through the sale of a broad portfolio of pharmaceutical products, with a focus on traditional Chinese medicine, which offers unique pricing power due to its cultural significance and demand. The company's competitive advantages include a robust R&D pipeline, strong relationships with healthcare providers, and a well-established distribution network across China.
Regulatory approvals for new drug applications
Changes in healthcare policies affecting pharmaceutical pricing
Market expansion efforts in Southeast Asia
R&D breakthroughs in traditional Chinese medicine
Regulatory changes impacting drug pricing and approvals
Technological disruption in drug development processes
Intense competition from both domestic and international pharmaceutical companies
Potential for generic drug competition affecting margins
High debt levels leading to increased financial risk
Liquidity concerns due to low operating margins
moderate - The pharmaceutical sector is somewhat insulated from economic downturns, but demand can be affected by consumer spending and healthcare budgets.
Interest rates impact Luyan Pharma's financing costs, particularly given its high debt-to-equity ratio of 2.13, which could affect profitability and investment in R&D.
minimal - The company is not heavily reliant on credit markets for its operations.
value - Investors may be attracted due to the low price-to-sales ratio of 0.2x, indicating potential undervaluation.
high - The stock has shown significant volatility, evidenced by a 3-month return of -23.4%.
